Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer-Reference-Cited by-同舟云学术

Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer

Published:2018-08-20 Issue:10 Volume:9 Page:1291-1299
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Takeda Takayuki¹^ORCID,Takeuchi Mayumi¹,Saitoh Masahiko¹,Takeda Sorou¹

Affiliation:

1. Department of Respiratory Medicine; Uji-Tokushukai Medical Center; Kyoto Japan

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1759-7714.12838/fullpdf

Reference49 articles.

1. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

2. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

3. Oncology meets immunology: The cancer-immunity cycle;Chen;Immunity,2013

4. Immune checkpoint therapy for non-small-cell lung cancer: An update;Xia;Immunotherapy,2016

5. Immunological studies on PD-1 deficient mice: Implication of PD-1 as a negative regulator for B cell responses;Nishimura;Int Immunol,1998

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combining dynamics of serum inflammatory and nutritional indicators as novel biomarkers in immune checkpoint inhibitor treatment of non-small-cell lung cancer with bone metastases;International Immunopharmacology;2024-07

2. Transcatheter arterial chemoembolisation combined with lenvatinib and cabozantinib in the treatment of advanced hepatocellular carcinoma;International Immunopharmacology;2024-03

3. G-CSF improving combined whole brain radiotherapy and immunotherapy prognosis of non-small cell lung cancer brain metastases;International Immunopharmacology;2024-03

4. Predictive Value of NLR and PLR in Driver-Gene-Negative Advanced Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors: A Single Institutional Cohort Study;Technology in Cancer Research & Treatment;2024-01

5. Important Biomarkers for Better Evaluation of Checkpoint Inhibitors and Other Immunotherapies in Lung Cancer;Immunotherapy Against Lung Cancer;2024